It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch.
Arecor Therapeutics plc has signed a co-development agreement with Sequel Med Tech LLC to combine AT278 (500U/mL) with Sequel’s twiist™ Automated Insulin Delivery (AID) system powered by Tidepool, and a royalty financing agreement with Ligand which will raise non-dilutive capital of up to $11 million (£8.2 million).
Parkinson’s UK awarded Cellestial Health £55,000 to continue exploring networks of brain cells called astrocytes that may hold answers for new treatments for Parkinson’s.
In this blog, Alan Griffith, Head of CDMO Global Operations, shares their achievements, priorities, and ambitions as a new member of the BIA community.
In this blog, Ivana Visnjic-Lynch, Marketing Manager at ZAGENO, discusses the race for breakthrough therapies and the need for effective R&D spend management which enables technology to unlock the future.
In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.
MDC and King’s College London have been awarded £400,000 funding from The Brain Tumour Charity to develop a groundbreaking new approach to treat glioblastoma, for patient benefit.
In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.
In this blog, Abby Clark builds on a round table the BIA hosted with Chi Onwurah MP and Newcastle life science companies to explore the landscape and the drivers which make the sector strong, yet undervalued.
Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026
Tailor Bio announced the publication of a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.
The Chancellor’s Spending Review, delivered on 11 June, outlines major investment priorities for 2026–2030 with big implications for life sciences. From UKRI to the NHS, find out what it means for the sector and what to expect from the upcoming Industrial Strategy. Watch this webinar and listen in on BIA experts as they unpack the headlines.
BIA has released a new explainer highlighting why the UK is well-positioned to lead in functional genomics, thanks to its unparalleled research capacity and exceptional talent pool.
This report from the BIA delves into the strategic importance of functional genomics, highlighting its potential to drive innovation across diverse applications, particularly in healthcare.
In this blog Richard Turner, the new vice chair of FTAC, examines the UK's overhauled R&D tax regime, which provides competitive incentives and a stable fiscal framework.
